key: cord-0952986-4zoibhdz
authors: Kondratiuk, Alexandra L; Pillay, Timesh D; Kon, Onn Min; Lalvani, Ajit
title: A conceptual framework to accelerate the clinical impact of evolving research into long COVID
date: 2021-04-22
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00136-5
sha: 635c509edee1a8a530dc56c80c10d4575a83a77c
doc_id: 952986
cord_uid: 4zoibhdz

nan

A conceptual framework to accelerate the clinical impact of evolving research into long COVID With more than 122 million cases of COVID-19 reported globally, and with a growing second pandemic wave underway, the long-term consequences of COVID-19 are an urgent public health priority. 1 An international survey of individuals with so-called long COVID reported a wide range of symptoms that persisted for months and resulted in substantial disability. 2 Latest UK estimates from an unweighted sample of 9063 individuals with COVID-19 suggest that 22% of individuals still have symptoms 5 weeks after initial infection, and 10% still have symptoms at 12 weeks. 3 People with long COVID have struggled to be heard, and it is encouraging that the scientific and medical communities are finally listening. In the UK, a five-point National Health Service plan has allocated £10 million to support sufferers of long COVID through specialist clinics and an online rehabilitation service, alongside £20 million for National Institute for Health Research (NIHR)-funded research. 4 Although, for any positive therapeutic relationship, it is essential that clinicians listen to their patients, this alone is rarely sufficient to treat symptoms. Understanding and treating long COVID will require an intense, rapid, and multidisciplinary research effort.

A key challenge to treating long COVID is the absence of a universally recognised case definition, including pathological correlates. It is not known whether long COVID is a novel and distinct syndrome, or multiple, partly overlapping syndromes presenting alone or in combination, and how much of this syndrome is accounted for by post-intensive care syndrome (seen after intensive care admission for non-COVID-19 illness), post-viral fatigue syndrome, or post-traumatic stress disorder. 5 We propose an overarching conceptual research framework to help define long COVID at the clinical and pathological level and rapidly deliver patient benefit through risk-stratified targeting of preventive and therapeutic interventions.

Current evidence suggests that COVID-19 can have long-term effects on body systems, including pulmonary, cardiovascular, renal and nervous system, and psychological effects. The most common symptoms of long COVID include fatigue, breathlessness, cough, loss of taste or smell (or both), myalgia, and gastrointestinal disturbance. 2,3,6,7 Persistent symptoms seem more likely to occur after severe disease than after non-severe disease, with the people who had intensive care unit treatment reporting the most pronounced symptoms in the convalescent period. 8 However, even individuals with mild COVID-19 report pronounced symptoms weeks or months after acute disease. 3, 7 Persistent symptoms have been associated with evidence of multi-organ damage, even in young, low-risk populations;⁹ however, only a small proportion of these symptoms are currently accounted for pathologically. Understanding the histo pathological and pathophysiological correlates of these symptoms is therefore a top priority for COVID-19 research, and clinical services should develop in parallel with this new information as it emerges.

Conversely, COVID-19 might cause long-term organ pathology in the absence of symptoms. For example, one study reported abnormal lung function in one in four patients 3 months after leaving hospital. Reduced diffusion capacity of the lung was predicted by coagulation markers during acute disease, suggesting that reduced lung function could be due to underlying vascular pathology. However, respiratory symptoms had resolved by this point for most patients in the study. 6 Signs of myocardial inflammation on cardiac MRI also persist for many weeks after acute COVID-19, yet the clinical consequences of this are unclear. 10 The medical community should be cautious when interpreting abnormal pathology; these findings might be clinically relevant, or could be transient and perhaps even nonspecific for COVID-19, reflecting any severe viral illness instead.

To facilitate an improved understanding and synthesis of research findings across studies and accelerate progress towards clear case definitions, we propose a conceptual framework that delineates the long-term sequelae of COVID-19 into three distinct categories (appendix p 1). The categories are: persistent symptoms with causal pathological correlates; persistent symptoms without pathophysiological correlates and the causative pathology is unknown; and organ pathology without associated symptoms or clinical consequence.

To maximise the clinical impact of research into long COVID, we propose two priorities to guide investigation. The first research priority is that predictive markers of the long-term sequelae of COVID-19 should be identified, including predictive markers present before infection (eg, patient age or pre-existing comorbidities), during acute illness (eg, clinical and biochemical markers), and during early convalescence (eg, functional and radiological indicators). These markers will allow clinicians to direct interventions to people most at risk of long COVID. The second research priority is to identify clinical interventions through purpose-designed studies to reduce the sequelae of COVID-19 with medium and long-term clinical outcomes. Such interventions should be developed and evaluated for each of the stages of SARS-CoV-2 infection-ie, pre-infection, acute illness, and early convalescence. Appendix p 2 shows a roadmap to develop a clinical toolkit for risk stratification and biomarker-guided interventions that will help to shape the nascent clinical services required for the rapidly growing population of COVID-19 survivors. The NIHRfunded Post-Hospitalisation COVID-19 Study (PHOSP-COVID) cohort exemplifies the prospective, longitudinal study design that can address these key questions.

The medical community has just started to recognise the high numbers of people who could be affected by long COVID. We propose our framework to help guide future research, enabling resources to be targeted efficiently to maximise the medical community's ability to deliver evidence-based solutions to the long-term effects of COVID-19. 

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Updated estimates of the prevalence of long COVID symptoms

NHS to offer 'long covid' sufferers help at specialist centres

A dynamic review of the evidence around ongoing covid-19 symptoms (often called long covid). National Insitute for Health Research

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19

Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation

Multi-organ impairment in low-risk individuals with long COVID

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)